The intersection of TB and HIV infection is increasing the global burden of both diseases. HIV infection greatly increases the risk of TB converting from latent to active infection, and TB infection increases morbidity and mortality in the HIV+ population. In 2006, the HU CFAR sponsored a national meeting on TBHIV coinfection, which led to the creation of a working group of HU CFAR members focused onTB-HlV research, and identification of a major unmet need: a BSL-3 biocontainment facility that would allow for cell sorting and imaging. When new facilities for the Ragon Institute were being constructed, the HU CFAR Membership successfully petitioned the Phillip T and Susan M Ragon Foundation to include a state of the art BSL-3 laboratory to meet these needs. These recently completed facilities include 2240 square feet of BSL- 3 level space, flow cytometry and cell sorting, animal handling, imaging and additional space to accommodate temporary equipment. With HU CFAR support this facility is now home of a newly created HU CFAR BSL-3 Core. Dr. Daniel Kavanagh serves as the PI, working closely with Dr Sarah Fortune, an internationally recognized expert in studies of TB who serves as Director of the newly-created Ragon TB Program, with close interactions with the HU CFAR TB-HIV Scientific Working Group. Drs. Fortune and Kavanagh jointly supervise a team of fellows, staff scientists, and a facility manager who bring extensive experience in safe and productive of BSL-3-level research. The combined talents of this team, as well as state-of-the-art BSL-3 facilities, are, available to the HU CFAR community. HU CFAR users are offered training and certification to conduct experiments within the facility;alternatively Core staff are available to carry out standard tissue culture and microbiology procedures on behalf of researchers who do not wish to work inside the facility. The proposed HU CFAR Biosafety Level 3 Core is guided by the following specific aims: 1. Provide training and consultation for members of HU CFAR community members who are planning TB related projects 2. Provide access to BSL-3 microbiology, tissue culture, live cell microscopy, live FACS, animal facilities, and special projects.

Public Health Relevance

Considered independently, the HIV and TB epidemics represent two of the greatest global health challenges of our time. As such, the HU CFAR leadership has placed HIV-TB research as a top priority area for research. The proposed BSL-3 Core will address several areas of significance including insights into pathogenesis, international engagements, biocontainment needs, and fostering of research synergies.

National Institute of Health (NIH)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Harvard Medical School
United States
Zip Code
Ballandras-Colas, Allison; Brown, Monica; Cook, Nicola J et al. (2016) Cryo-EM reveals a novel octameric integrase structure for betaretroviral intasome function. Nature 530:358-61
Jain, Sachin; Oldenburg, Catherine E; Mimiaga, Matthew J et al. (2016) High Levels of Concomitant Behavioral Health Disorders Among Patients Presenting for HIV Non-occupational Post-exposure Prophylaxis at a Boston Community Health Center Between 1997 and 2013. AIDS Behav 20:1556-63
Sunshine, Sara; Kirchner, Rory; Amr, Sami S et al. (2016) HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay. J Virol 90:4511-9
Krakower, Douglas S; Mayer, Kenneth H (2016) Renal Function and Tenofovir Disoproxil Fumarate for Preexposure Prophylaxis: How Safe Is Safe Enough? J Infect Dis 214:983-5
Mayer, Kenneth H; Krakower, Douglas S; Boswell, Stephen L (2016) Antiretroviral Preexposure Prophylaxis: Opportunities and Challenges for Primary Care Physicians. JAMA 315:867-8
Saito, Akatsuki; Henning, Matthew S; Serrao, Erik et al. (2016) Capsid-CPSF6 Interaction Is Dispensable for HIV-1 Replication in Primary Cells but Is Selected during Virus Passage In Vivo. J Virol 90:6918-35
Krakower, Douglas S; Maloney, Kevin M; Grasso, Chris et al. (2016) Primary care clinicians' experiences prescribing HIV pre-exposure prophylaxis at a specialized community health centre in Boston: lessons from early adopters. J Int AIDS Soc 19:21165
Brown, Carolyn A; Suneja, Gita; Tapela, Neo et al. (2016) Predictors of Timely Access of Oncology Services and Advanced-Stage Cancer in an HIV-Endemic Setting. Oncologist 21:731-8
McDavitt, Bryce; Bogart, Laura M; Mutchler, Matt G et al. (2016) Dissemination as Dialogue: Building Trust and Sharing Research Findings Through Community Engagement. Prev Chronic Dis 13:E38
Gandhi, Rajesh T; Kwon, Douglas S; Macklin, Eric A et al. (2016) Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial. J Acquir Immune Defic Syndr 71:246-53

Showing the most recent 10 out of 844 publications